PNN

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

Retrieved on: 
Wednesday, November 29, 2023
RNA, Protein, Regeneration, Small RNA, Spinal cord, Human, Exosome, Tetraplegia, Fig, Patent, CNS, NRX, PNN, Neuron, Vaccine

The biopharmaceutical company is using its biologically-guided exosome therapy ExoTherapy platform to expand its portfolio of products that will address spinal cord injuries and regeneration of neurons in other CNS indications.

Key Points: 
  • The biopharmaceutical company is using its biologically-guided exosome therapy ExoTherapy platform to expand its portfolio of products that will address spinal cord injuries and regeneration of neurons in other CNS indications.
  • In the latest development, NurExone has developed two selective small inhibiting RNA sequences (siRNA) that target and inhibit proteins within the Peri-Neural Network (PNN) complex (Fig.
  • The breakthrough sequences, detailed in a patent application held by the Company, are built upon a scientifically validated strategy for enhanced neuronal regeneration via inhibition of the PNN complex.
  • The Company believes that its innovative approach, using the Company’s ExoTherapy platform to deliver these RNA sequences, will overcome limitations of previous methods.

Aerin Medical Announces Sustained Clinical and Quality-of-Life Improvements Two Years After Chronic Rhinitis Treatment with RhinAer®

Retrieved on: 
Tuesday, December 5, 2023
General Health, Health, Clinical Trials, Medical Devices, Mucous membrane, PNN, Ear, Longevity, Congestion, Nose, Patient, Multimedia, Itch, Sneeze, ENT, CMS, Trial of the century, Medicare, Otorhinolaryngology, Physician, Quality of life, Radiofrequency ablation, Cough, Inflammation, Pharmaceutical industry, Dietary supplement

RELIEF demonstrated that a single procedure with RhinAer®, a temperature-controlled, radiofrequency technology, resulted in sustained improvements in chronic rhinitis symptoms, including post-nasal drip and chronic cough, and quality of life through two years along with a substantial decrease in chronic rhinitis medication usage.

Key Points: 
  • RELIEF demonstrated that a single procedure with RhinAer®, a temperature-controlled, radiofrequency technology, resulted in sustained improvements in chronic rhinitis symptoms, including post-nasal drip and chronic cough, and quality of life through two years along with a substantial decrease in chronic rhinitis medication usage.
  • View the full release here: https://www.businesswire.com/news/home/20231205015241/en/
    Two-year results of the RELIEF clinical trial published in The Laryngoscope confirm that a single procedure with RhinAer® resulted in sustained improvements in chronic rhinitis symptoms and quality of life, along with a substantial decrease in chronic rhinitis medication usage.
  • RhinAer, a non-invasive technology developed by Aerin Medical Inc., uses temperature-controlled, radiofrequency energy to provide relief from chronic rhinitis.
  • ENTs use RhinAer as a non-invasive alternative to surgical interventions to directly interrupt nerve signals and help reduce chronic rhinitis symptoms.

Neurent Medical Announces New CPT Code® for Chronic Rhinitis Treatment Offering Significant Symptom Improvements

Retrieved on: 
Monday, November 13, 2023
PNN, Sleep, Safety, Prevalence, Congestion, Nose, Medical classification, CPT, Patient, FACS, Inflammation, Sneeze, ENT, CMS, Partnership, CLARITY, Growth, Medicare, Rhinorrhea, Public, Physician, Radiofrequency ablation, Northwest Kidney Centers

GALWAY, Ireland, Nov. 13, 2023 /PRNewswire/ -- Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced a significant milestone for the chronic rhinitis market. The Centers for Medicare and Medicaid Services (CMS) has recently assigned a Category I Current Procedural Terminology (CPT®) reimbursement code for a breakthrough minimally invasive procedure designed to address the symptoms of patients suffering from chronic rhinitis.

Key Points: 
  • GALWAY, Ireland, Nov. 13, 2023 /PRNewswire/ -- Neurent Medical , a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced a significant milestone for the chronic rhinitis market.
  • The establishment of this CPT code is a significant milestone for physicians who treat chronic rhinitis patients.
  • The new code describes the procedure performed by otolaryngologists or ear, nose, and throat (ENT) physicians when disrupting overactive nerves that drive chronic rhinitis symptoms.
  • It is estimated that several million chronic rhinitis patients are seen by ENT doctors annually in the United States.

Aerin Medical Announces Advances for Chronic Rhinitis Treatment with New CPT® Code and Final CMS-Established Payment Rates

Retrieved on: 
Friday, November 3, 2023
Medical Supplies, Health, Medical Devices, Health Technology, Other Health, Other Science, Science, PNN, ENT, Education, Medicare, Aerin Lauder, Ear, Physician, American Medical Association, Nose, Rhinorrhea, MBA, Radiofrequency ablation, AMA, Multimedia, Congestion, Partnership, Center for Medicare and Medicaid Innovation, Allergy, CPT, Patient, Centers for Medicare & Medicaid Services, CMS, Thomas Jefferson University, Hospital, Nursing, Health insurance

The new code describes the procedure performed by ENT physicians when treating overactive nerves that drive chronic rhinitis symptoms with Aerin Medical’s RhinAer®.

Key Points: 
  • The new code describes the procedure performed by ENT physicians when treating overactive nerves that drive chronic rhinitis symptoms with Aerin Medical’s RhinAer®.
  • View the full release here: https://www.businesswire.com/news/home/20231031993246/en/
    CMS is set to implement a new CPT code that improves access to chronic rhinitis treatment with RhinAer® for patients often stuck in an unproductive cycle of care.
  • RhinAer is supported by a strong body of clinical evidence demonstrating significant, durable symptom improvement for chronic rhinitis patients.
  • Treatment with RhinAer is non-invasive and can be performed by ENT physicians in the office and outpatient surgical settings.

LBank Exchange Will List PEGO Network (PG) on July 17, 2023

Retrieved on: 
Monday, July 17, 2023
DAO, PNN, NFT, PG, EVM, Ecosystem, Validator, Cryptocurrency, Dapp

Road Town, British Virgin Islands--(Newsfile Corp. - July 17, 2023) - LBank Exchange, a global digital asset trading platform, will list PEGO Network (PG) on July 17, 2023.

Key Points: 
  • Road Town, British Virgin Islands--(Newsfile Corp. - July 17, 2023) - LBank Exchange, a global digital asset trading platform, will list PEGO Network (PG) on July 17, 2023.
  • For all users of LBank Exchange, the PG/USDT trading pair will be officially available for trading at 8:00 UTC on July 17, 2023.
  • LBank Exchange is thrilled to announce the upcoming listing of PEGO Network (PG), a Web3 infrastructure that provides high autonomy, scalability, and sustainability for decentralized applications.
  • The PEGO network supports multi-language programming, has a virtual machine for smart contracts, and offers open interfaces for developers.

Ultra Lithium Sells Laguna Verde for Share Stake in Power Minerals

Retrieved on: 
Wednesday, May 17, 2023
Lithium, Term sheet, PNN, TSX Venture Exchange, Catamarca Province, OTCQB, ASX, AUD, Acquisition, TSX, LCE, Lego Power Miners, Security (finance), Power

Ultra Lithium’s CEO Weiguo Lang stated, “As a result of recent changes to Canadian Government regulations with respect to critical minerals, Ultra Lithium allowed its previous agreement to explore and develop the Laguna Verde project with Zangge Mining to expire.

Key Points: 
  • Ultra Lithium’s CEO Weiguo Lang stated, “As a result of recent changes to Canadian Government regulations with respect to critical minerals, Ultra Lithium allowed its previous agreement to explore and develop the Laguna Verde project with Zangge Mining to expire.
  • We look forward to jointly exploring and developing the Laguna Verde project with Power Minerals.
  • Subject to satisfactory due diligence, Power and Ultra Lithium will enter into a definitive Acquisition Agreement covering all key commercial terms including the share distributions.
  • Prior to completion of the proposed transaction, Ultra Lithium will transfer certain mineral properties not forming part of the Laguna Verde project out of Ultra Argentina SARL and Ultra Minerals S.A. for retention.

New Data show NEUROMARK® Chronic Rhinitis Treatment Offers Significant Symptom Improvements

Retrieved on: 
Tuesday, March 21, 2023
Biotechnology, General Health, Health, Medical Devices, Congestion, Medicine, PNN, Rhinorrhea, VAS, Inflammation, Șaeș, Otorhinolaryngology, Nose, Visual analogue scale, Patient, Swelling, CLARITY, Sneeze, The Rheumatoid Arthritis Quality of Life Questionnaire, Nasal congestion, Pharmaceutical industry

These data, published in Laryngoscope Investigative Otolaryngology , show that patients receiving the NEUROMARK therapy demonstrated significant improvement in rhinorrhea and nasal congestion symptoms at 3 months.

Key Points: 
  • These data, published in Laryngoscope Investigative Otolaryngology , show that patients receiving the NEUROMARK therapy demonstrated significant improvement in rhinorrhea and nasal congestion symptoms at 3 months.
  • NEUROMARK’s unique device and intelligent technology platform enable otolaryngologists to treat chronic rhinitis with precision and control, which in turn allows for an enhanced patient experience from treatment through recovery.
  • Total Nasal Symptom Score (rTNSS) and mini Rhinoconjunctivitis Quality of Life Questionnaire (mini RQLQ) score were also evaluated.
  • “We’re encouraged by the three-month CLARITY data demonstrating the safety, efficacy and relief from chronic rhinitis symptoms that can be achieved with NEUROMARK,” said Neurent Medical CEO Brian Shields.

Neurent Medical Announces Limited Market Release of NEUROMARK® System to Treat Chronic Rhinitis

Retrieved on: 
Friday, February 3, 2023
Neurology, Medical Devices, Other Health, Health, Health Technology, Nose, AMA, American Medical Association, Swelling, American Academy of Otolaryngology–Head and Neck Surgery, Rhinorrhea, Patient, Inflammation, Otorhinolaryngology, Sneeze, Nasal cavity, Intelligence, CPT, American Academy, RNT, Medicine, Surgeon, PNN, Dentistry

Neurent Medical , a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMARK® Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets.

Key Points: 
  • Neurent Medical , a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal diseases, today announced its NEUROMARK® Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets.
  • Commercialization comes as the American Medical Association (AMA) issued a new Category I Current Procedural Terminology (CPT®) code for posterior nasal nerve ablation (PNN) procedures, which includes NEUROMARK, to treat chronic rhinitis.
  • NEUROMARK’s unique device and intelligent technology platform enable Otolaryngologists to treat chronic rhinitis patients with precision and control and enhance the patient experience from treatment through recovery.
  • The recent endorsement2 of PNN by the AAO-HNS, a specialty society representing almost 12,000 ENT surgeons, further validates Neurent Medical’s long-term future in the treatment of chronic rhinitis.

Arqit partners with Nine23 to provide secure cloud services on G-Cloud 13 for UK Government

Retrieved on: 
Tuesday, October 25, 2022
Cloud, Quantum, U.S. Securities and Exchange Commission, Time, Critical infrastructure, Communication, Risk, SEC, Government, National, PSN, Contract, PNN, Annual report, Nasdaq, Partnership, Technology, Private Securities Litigation Reform Act, Software, PKI, RLI, CEO, Form, Innovation, GLOBE, Forward-looking statement, Enterprise, HSCN, Solution, Platform, Cryptocurrency, Security (finance), Risk management

Nine23s proprietary Platform FLEX provides a multi-private cloud environment with direct network gateway connectivity to all UK government networks including the PSN, PNN, RLI, HSCN and others.

Key Points: 
  • Nine23s proprietary Platform FLEX provides a multi-private cloud environment with direct network gateway connectivity to all UK government networks including the PSN, PNN, RLI, HSCN and others.
  • The services will be available on the new G-Cloud 13 framework via the Digital Marketplace.
  • G-Cloud 13, provides hosting and software services, together with associated support services to UK government departments, other public sector bodies, and Enterprise customers supporting Critical National Infrastructure.
  • Commenting, David Williams, Arqit Founder, Chairman and CEO, said "We are pleased to work with Nine23 to deliver our product to classified UK government projects.

Aerin Medical Announces Establishment of a New CPT® Code for Endoscopic Destruction of the Posterior Nasal Nerve Using Radiofrequency Ablation

Retrieved on: 
Tuesday, October 18, 2022
Medical Devices, Health, LinkedIn, Physician, Congestion, Panel Action Bingo, ENT, Nose, YouTube, CE marking, Patient, Indian Medical Association, CPT, Radiofrequency ablation, Twitter, PNN, Instagram, Surgeon, Multimedia, Tissue, Stylus, Ear, Mucus, RF, Rhinorrhea, CEO, American Medical Association, AMA, Randomized controlled trial, Â, FDA, Solution, Pharmaceutical industry, Facebook

This information was released by the AMA in the Summary of Panel Actions from the September CPT Editorial Panel meeting.

Key Points: 
  • This information was released by the AMA in the Summary of Panel Actions from the September CPT Editorial Panel meeting.
  • The RhinAer Stylus precisely applies RF energy to overactive nerves in the back of the nose, reducing chronic rhinitis symptoms.
  • View the full release here: https://www.businesswire.com/news/home/20221018005272/en/
    A new Category I CPT code for endoscopic destruction of the posterior nasal nerve using radiofrequency ablation will be effective January 1, 2024.
  • RhinAer directly disrupts the posterior nasal nerve (PNN) that triggers excessive mucus production, treating an underlying cause of chronic rhinitis.